What is claimed is:

1. The use of a compound that is (*R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy-propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof in the manufacture of a medicament for treating severe hypertriglyceridemia in a subject, where severe hypertriglyceridemia refers to a serum triglyceride level of at least 10 mM.

2. The use of claim 1 where the MBX-8025 or an MBX-8025 salt is MBX-8025 L-lysine dihydrate salt.

3. The use of claim 1 or 2 where the medicament is intended for oral administration.

4. The use of any one of claims 1 to 3 where the dose of the compound is 20 – 200 mg/day when the dose is calculated as (*R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxypropyl)thio)-2-methylphenoxy)acetic acid.

5. The use of claim 4 where the dose of the compound is 50 – 200 mg/day when the dose is calculated as (*R)*-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxypropyl)thio)-2-methylphenoxy)acetic acid.

6. The use of any one of the previous claims where the medicament is intended to be administered once/day.

7. The use of any one of claims 1 to 6 where the subject is also to be administered a fibrate.

8. The use of claim 7 where the fibrate is gemfibrozil, fenofibrate, choline fenofibrate, bezafibrate, or ciprofibrate.

9. The use of any one of claims 1 to 6 where the subject is also to be administered niacin.

10. The use of any one of claims 1 to 6 where the subject is also to be administered an omega-3 fatty acid.

11. The use of any one of claims 1 to 6 where the subject is also to be administered two or more of a fibrate, niacin, and an omega-3 fatty acid.

12. The use of claim 11 where the subject is also to be administered three of a fibrate, niacin, and an omega-3 fatty acid.

°°

13. The use of any one of the previous claims where the subject is also to be treated by apheresis.

14. The use of any one of claims 1 to 13 where severe hypertriglyceridemia refers to a serum triglyceride level of at least 1000 mg/dL.

15. The use of any one of claims 1 to 13 where severe hypertriglyceridemia refers to a serum triglyceride level of at least 20 mM.

16. The use of any one of claims 1 to 13 where severe hypertriglyceridemia refers to a serum triglyceride level of at least 2000 mg/dL.

17. The use of any one of the previous claims where the severe hypertriglyceridemia is Type I or Type V hyperlipoproteinemia.

18. The use of claim 17 where the severe hypertriglyceridemia is Type I hyperlipoproteinemia.

19. The use of claim 17 where the severe hypertriglyceridemia is Type V hyperlipoproteinemia.

20. The use of any one of the previous claims where the severe hypertriglyceridemia is refractory.

°°